Faleck DM, et al. - Researchers used a multicenter consortium cohort study of the real-world experience with vedolizumab to assess the impact of disease duration on the efficacy of vedolizumab. In patients with Crohn’s disease (CD) and ulcerative colitis (UC) treated with vedolizumab, they analyzed rates of clinical and endoscopic remission, comparing patients with shorter disease duration (≤2 years) with patients with longer-standing (>2 years) disease. From May 2014 through December 2016, data from a retrospective, multicenter, consortium of patients with CD or UC treated with vedolizumab were analyzed. Compared to patients with longer disease duration, those with CD for 2 years or less are significantly more likely to achieve a complete response, corticosteroid-free remission (CSFR), or endoscopic response to vedolizumab. In patients with UC, disease duration does not correlate with response vedolizumab.